NQo1-dependent redox cycling of idebenone: Effects on cellular redox potential and energy levels

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Haefeli, Roman H ^a,b   Erb, Michael ^a   Gemperli, Anja C ^c   Robay, Dimitri ^a   Fruh, Isabelle ^d   Anklin, Corinne ^a   Dallmann, Robert ^e   Gueven, Nuri ^a  

^a Santhera Pharmaceuticals   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c INSTITUT STRAUMANN AG   (Switzerland)

^d NOVARTIS PHARMA AG   (Switzerland)

^e UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; DICOUMAROL; IDEBENONE; LACTIC ACID; MESSENGER RNA; QUINONE DERIVATIVE; RECOMBINANT ENZYME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROTENONE; SUCCINATE DEHYDROGENASE (UBIQUINONE); UBIDECARENONE; UBIQUINONE 1; UNCLASSIFIED DRUG; DRUG DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE; UBIQUINONE; UBIQUINONE Q1;

ADOLESCENT; ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CELL ISOLATION; CELL LEVEL; CELL METABOLISM; CEREBROVASCULAR ACCIDENT; COMPLEX I DEFICIENCY; CONTROLLED STUDY; CYTOSOL; CYTOTOXICITY TEST; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; EMBRYO; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HYBRID CELL; IC 50; IN VITRO STUDY; LACTIC ACIDOSIS; LIPOPHILICITY; MALE; MITOCHONDRIAL ENCEPHALOPATHY; MITOCHONDRIAL ENERGY TRANSFER; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; OXIDATION REDUCTION POTENTIAL; PROTEIN FUNCTION; RAT; RESPIRATORY CHAIN; ANIMAL; CELL CULTURE; CELL LINE; CELL STRAIN HEK293; CELL STRAIN HEPG2; GENETICS; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; OXIDATION REDUCTION REACTION; TUMOR CELL LINE;

ADENOSINE TRIPHOSPHATE; ANIMALS; CELL LINE; CELL LINE, TUMOR; CELLS, CULTURED; FEMALE; HEK293 CELLS; HEP G2 CELLS; HUMANS; LACTIC ACID; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; NAD; NAD(P)H DEHYDROGENASE (QUINONE); OXIDATION-REDUCTION; QUINONES; RATS; ROTENONE; UBIQUINONE;

EID: 79953306267     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017963     Document Type: Article

References (49)

1. O'Brien PJ, (1991) Molecular mechanisms of quinone cytotoxicity. Chem Biol Interactions 80: 1-41.
2. Monks TJ, Hanzlik RP, Cohen GM, Ross D, Graham DG, (1992) Contemporary issues in toxicology. Toxicol Appl Pharmacol 112: 2-16.
3. Long DJ II, Jaiswal AK, (2000) NRH:quinone oxidoreductase2 (NQO2). Chem Biol Interact 129: 99-112.
4. Colucci MA, Moody CJ, Gouch GD, (2008) Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential. Org Biomol Chem 6 (4): 637-56.
5. Pink JJ, Planchon SM, Tagliarino C, Varnes ME, Siegel D, et al. (2000) NAD(P)H:Quinone oxidoreductase activity is the principal determinant of β-lapachone cytotoxicity. J Biol Chem 275: 5416-5424.
6. Adikesavan AK, Barrios R, Jaiswal AK, (2007) In vivo role of NAD(P)H:Quinone oxidoreductase 1 in metabolic activation of mitomycin C and bone marrow cytotoxicity. Cancer Res 67: 7966-7971.
7. Boutin JA, Chatelain-Egger F, Vella F, Delagrangea P, Ferry G, (2005) Quinone reductase 2 substrate specificity and inhibition pharmacology. Chem Biol Interact 151: 213-228.
8. Chan TS, Teng S, Wilson JX, Galati G, Khan S, et al. (2002) Coenzyme Q cytoprotective mechanisms for mitochondrial complex I cytopathies involves NAD(P)H: quinone oxidoreductase 1 (NQO1). Free Radic Res 36: 421-7.
9. Dragan M, Dixon SJ, Jaworski E, Chan TS, O'Brien PJ, et al. (2006) Coenzyme Q(1) depletes NAD(P)H and impairs recycling of ascorbate in astrocytes. Brain Res 1078: 9-18.
10. Suno M, Akinobu N, (1984) Inhibition of lipid peroxidation by a novel compound (CV-2619) in brain mitochondria and mode of action of the inhibition. Biochem Biophys Res Comm 125: 1046-1052.
11. Sugiyama Y, Fujita T, Matsumoto M, Okamoto K, Imada I, (1985) Effects of idebenone (CV-2619) and its metabolites on respiratory activity and lipid peroxidation in brain mitochondria from rats and dogs. J Pharmacobio-Dyn 8: 1006-1017.
12. Suno M, Akinobu N, (1989) Inhibition of lipid peroxidation by idebenone in brain mitochondria in the presence of succinate. Arch Gerontol Geriatr 8: 291-297.
13. Rauchovà H, Vrbacky M, Bergamini C, Fato R, Lenaz G, et al. (2006) Inhibition of glycerophosphate-dependent H2O2 generation in brown fat mitochondria by idebenone. Biochem Biophys Res Comm 339: 362-366.
14. Ranganathan S, Harmison GG, Meyertholen K, Pennuto M, Burnett BG, et al. (2009) Mitochondrial abnormalities in spinal and bulbar muscular atrophy. Hum Molr Genet 18: 27-42.
15. Jauslin ML, Wirth T, Meier T, Schoumacher F, (2002) A cellular model for Friedreich Ataxia reveals small-molecule glutathione peroxidase mimetics as novel treatment strategy. Human Mol. Genet 11: 3055.
16. Kutz K, Drewe J, Vankan P, (2009) Pharmacokinetic properties and metabolism of idebenone. J Neurol 256: 31-3.
17. Haginoya K, Miyabayashi S, Kikuchi M, Kojima A, Yamamoto K, et al. (2009) Efficacy of idebenone for respiratory failure in a patient with Leigh syndrome: a long-term follow-up study. J Neurol Sci 278: 112-4.
18. Ikejiri Y, Mori E, Ishii K, Nishimoto K, Yasuda M, et al. (1996) Idebenone improves cerebral mitochondrial oxidative metabolism in a patient with MELAS. Neurology 47: 583-5.
19. Napolitano A, Salvetti S, Vista M, et al. (2000) Long-term treatment with idebenone and riboflavin in a patient with MELAS. Neurol Sci 21: 981-2.
20. Tonon C, Lodi R, (2008) Idebenone in Friedreich's Ataxia. Expert Opin Pharmacother 9: 2327-2337.
21. Myers L, Farmer JM, Wilson RB, Friedman L, Tsou A, et al. (2008) Antioxidant use in Friedreich ataxia. J Neurol Sci 267: 174-6.
22. Rötig A, de Lonlay P, Chretien D, (1997) Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet 7: 215-17.
23. Houchi H, Azuma M, Oka M, Morita K, (1991) Idebenone inhibits catecholamine secretion through its blocking action on Ca2+ channels in cultured adrenal chromaffin cells. Jpn J Pharmacol 57: 553-8.
24. Takuma K, Yoshida T, Lee E, Mori K, Kishi T, et al. (2000) CV-2619 protects cultured astrocytes against reperfusion injury via nerve growth factor production. Eur J Pharmacol 406: 333-9.
25. Rauchová H, Drahota Z, Bergamini Z, Fato R, Lenaz G, (2008) Modification of respiratory-chain enzyme activities in brown adipose tissue mitochondria by idebenone (hydroxydecyl-ubiquinone). J Bioenerg Biomembr 40: 85-93.
26. Civenni G, Bezzi P, Trotti D, Volterra A, Racagni G, (2009) Inhibitory effect of the neuroprotective agent idebenone on arachidonic acid metabolism in astrocytes. Eur J Pharmacol 370: 161-7.
27. Chapela SP, Burgos HI, Salazar AI, Nievas I, Kriguer N, et al. (2008) Biochemical study of idebenone effect on mitochondrial metabolism of yeast. Cell Biol Int 32: 146-50.
28. James AM, Cochemé HM, Smith RA, Murphy MP, (2005) Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species. Implications for the use of exogenous ubiquinones as therapies and experimental tools. J Biol Chem 280: 21295-312.
29. Degli Esposti M, Ngo A, Ghelli A, Benelli B, Carelli B, et al. (1996) The interaction of Q analogs, particularly hydroxydecyl-benzoquinone (idebenone), with the respiratory complexes of heart mitochondria. Arch Biochem Biophys 330: 395-400.
30. Brière JJ, Schlemmer D, Chretien D, Rustin P, (2004) Quinone analogues regulate mitochondrial substrate competitive oxidation. Biochem Biophys Res Comm 316: 1138-1142.
31. Fato R, Bergamini C, Bortolus M, Maniero AL, Leoni S, et al. (2008) Differential effects of mitochondrial Complex I inhibitors on production of reactive oxygen species. Biochim Biophys Acta 1787: 384-92.
32. Okamoto K, Watanabe M, Morimoto H, Imada I, (1998) Synthesis, metabolism, and in vitro biological activities of 6-(10-hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone (CV-2619)-related compounds. Chem Pharm Bull (Tokyo) 36: 178-89.
33. Mayer LD, Hope MJ, Cullis PR, Janoff AS, (1985) Solute distributions and trapping efficiencies observed in freeze-thawed multilamellar vesicles. Biochim Biophys Acta 817: 193-196.
34. Paolino D, Iannone M, Cardile V, Renis M, Puglisi G, et al. (2004) Tolerability and improved protective action of idebenone-loaded pegylated liposomes on ethanol-induced injury in primary cortical Astrocytes. J Pharmaceut Sci 93: 1815-1827.
35. Wu K, Knox R, Sun XZ, Joseph P, Jaiswal AK, et al. (1997) Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase. Arch Biochem Biophys 347: 221-228.
36. Knox RJ, Jenkins TC, Hobbs SM, Chen S, Melton RG, et al. (2000) Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: A novel co-substrate-mediated antitumor prodrug therapy. Canc Res 60: 4179-4186.
37. Tan AS, Berridge MV, (2010) Evidence for NAD(P)H:quinone oxidoreductase 1 (NQO1)-mediated quinone-dependent redox cycling via plasma membrane electron transport: A sensitive cellular assay for NQO1. Free Radic Biol Med 48: 421-429.
38. Ernster L, Danielson L, Ljunggren M, (1962) DT Diaphorase. 1. Purification from the soluble fraction of rat-liver cytoplasm, and properties. Biochim Biophys Acta 58: 171-188.
39. Hwang JH, Kim DW, Jo EJ, Kim YK, Jo YS, et al. (2009) Pharmacological stimulation of NADH oxidation ameliorates obesity and related phenotypes in mice. Diabetes 58: 965-974.
40. Audi SH, Zhao H, Bongard RD, Hogg N, Kettenhofen NJ, et al. (2003) Pulmonary arterial endothelial cells affect the redox status of coenzyme Q0. Free Radic Biol Med 34: 892-907.
41. Beyer RE, Segura-Aguilar J, Di Bernardo S, Cavazzoni M, Fato R, et al. (1996) The role of DT-diaphorase in the maintenance of the reduced antioxidant form of coenzyme Q in membrane systems. Proc Natl Acad Sci U S A 93: 2528-32, 1996.
42. Lopéz LC, Quinzii CM, Area E, Naini A, Rahman S, et al. (2010) PLoS One 5 (7): e11897.
43. Pallotti F, Baracca A, Hernandez-Rosa E, Walker WF, Solaini G, et al. (2004) Biochemical analysis of respiratory function in cybrid cell lines harbouring mitochondrial DNA mutations. Biochem J 384: 287-93.
44. Villalba JM, Parrado C, Santos-Gonzalez M, Alcain FJ, (2010) Therapeutic use of coenzyme Q10 and coenzyme Q10-related compounds and formulations. Expert Opin Investig Drugs 19: 535-54.
45. Siegel D, Bolton EM, Burr JA, Liebler DC, Ross D, (1997) The reduction of alpha-tocopherolquinone by human NAD(P)H: quinone oxidoreductase: the role of alpha-tocopherolhydroquinone as a cellular antioxidant. Mol Pharmacol 52: 300-5.
46. Dinkova-Kostova AT, Talalay P, (2010) NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. Arch Biochem Biophys 501: 116-123.
47. Lenaz G, (2001) A critical appraisal of the mitochondrial coenzyme Q pool. FEBS Lett 509: 151-155.
48. Ernster, L, (1967) DT-diaphorase. Methods Enzymol 10: 309-317.
49. Gasdaska PY, Fisher H, Powis G, (1995) An alternatively spliced form of NQO1 (DT-Diaphorase) messenger RNAi the putative quinone substrate binding site is present in human normal and tumor tissues. Canc Res 55: 2542-2547.